|The myeloperoxidase-463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls|
|Chang, Cuixian1; Gao, Baorong2; Liu, Zheng1; Mao, Jianbin1; Jiang, Guoqiang1|
|关键词||Myeloperoxidase Polymorphism Coronary artery disease Atherosclerosis Meta-analysis|
|WOS标题词||Science & Technology|
|类目[WOS]||Medical Laboratory Technology|
|研究领域[WOS]||Medical Laboratory Technology|
|关键词[WOS]||MYOCARDIAL-INFARCTION ; HEALTHY-INDIVIDUALS ; LUNG-CANCER ; POPULATION ; ATHEROSCLEROSIS ; ASSOCIATION ; GENE|
Objectives: Genetic polymorphism of human myeloperoxidase (MPO) -463G/A has been implicated to alter the risk of coronary artery disease (CAD), but the results are controversial. To improve the reliability of the conflicting results, we conducted a meta-analysis of studies relating the MPO -463G/A polymorphism with the risk of CAD.
Design and methods: Two investigators independently searched the MEDLINE, EMBASE and Cochrane Library up to June, 2012. Summary odds ratios (OR) and 95% confidence interval (Cl) for the MPO -463G/A polymorphism and CAD risk were calculated, and potential sources of heterogeneity and publication bias were explored. Statistical analysis was performed with the software program of Stata 9.0.
Results:,5 case-control studies were finally identified for analyses, involving 1938 cases with CAD and 1990 controls. We found that the MPO -463G/A polymorphism has no significant association with overall CAD risk (GIG vs A/A: OR = 0.595, 95%CI = 0.298-1.188, P = 0.141; GIG vs G/A + A/A: OR = 0.886, 95%CI = 0.779-1.008, P = 0.066; G/G + G/A vs A/A: OR = 0.611, 95%CI = 0.334-1.119, P = 0.111; OR = 0.886, 95%CI = 0.779-1.008, P = 0.066; G vs A: OR = 0.843, 95%CI = 0.675-1.053, P = 0.133). The heterogeneity test showed that there were significant differences between individual studies in additive, recessive and allelic genetic models (P = 0.008, P = 0.021, P = 0.019, respectively); further analyses revealed that age and sex possibly account for the heterogeneity.
Conclusions: Our meta-analysis demonstrated the evidence that there was no significant association between the MPO -463G/A polymorphism and the risk of CAD; larger and well-designed multicenter studies are needed to confirm our results. (C) 2013 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
|作者单位||1.CAPF, Sichuan Prov Hosp, Dept Cardiol, Leshan 614000, Peoples R China|
2.Peking Univ, Peoples Hosp, Mol & Genet Unit, Dept Obstet & Gynecol, Beijing 100871, Peoples R China
|Chang, Cuixian,Gao, Baorong,Liu, Zheng,et al. The myeloperoxidase-463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls[J]. CLINICAL BIOCHEMISTRY,2013,46(16-17):1644-1648.|
|APA||Chang, Cuixian,Gao, Baorong,Liu, Zheng,Mao, Jianbin,&Jiang, Guoqiang.(2013).The myeloperoxidase-463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls.CLINICAL BIOCHEMISTRY,46(16-17),1644-1648.|
|MLA||Chang, Cuixian,et al."The myeloperoxidase-463G/A polymorphism and coronary artery disease risk: A meta-analysis of 1938 cases and 1990 controls".CLINICAL BIOCHEMISTRY 46.16-17(2013):1644-1648.|